Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials
CONCLUSION: Febuxostat 40 mg and dotinurad 2 mg tended to be more effective than benzbromarone 50 mg, while dotinurad 2 mg and benzbromarone 50 mg tended to be safer than febuxostat 40 mg in hyperuricemic patients with or without gout.PMID:34779393 | DOI:10.5414/CP204097
Source: International Journal of Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Young Ho Lee Gwan Gyu Song Source Type: research
More News: Drugs & Pharmacology | Gout